CytoVale: Funding, Investors & Team (Sep 2026)

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale Subscribe to our newsletter: http://eepurl.com/huCdiH

CytoVale has raised $184M across 2 rounds on record. The most recent is a Series D of $100M announced in Oct 2024.

CytoVale's most recent funding round on record is a Series D of $100M, announced in Oct 2024.

FundedIQ lists Ajay Shah (Founder) at CytoVale.

CytoVale is based in San Francisco, California, United States.

CytoVale is in the 11-50 employee band.

CytoVale's latest round of $100M is above the $5.7M median round size for Artificial Intelligence companies on FundedIQ across 7,234 tracked companies over the last two years.